esomeprazole + BI 1819479

Esomeprazole + BI 1819479 is a combination of a proton pump inhibitor, esomeprazole, and the investigational lysophospholipase inhibitor BI 1819479. Esomeprazole is widely used for acid suppression and has shown potential antifibrotic activity, while BI 1819479 is an orally administered small molecule in clinical development for idiopathic pulmonary fibrosis (IPF). BI 1819479 works by inhibiting lysophospholipase, which may slow or reverse fibrotic processes in the lungs. Recent clinical studies have assessed the pharmacokinetic interaction between esomeprazole and BI 1819479 and the safety/tolerability of concurrent administration, focusing on healthy volunteers and IPF patient cohorts.